Imatinib trough levels: A potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia

被引：0
|
作者：
Natarajan, H. [1 ]
Kumar, L. [2 ]
Bakhshi, S. [2 ]
Sharma, A. [2 ]
Velpandian, T. [1 ]
Gogia, A. [2 ]
Gupta, Y. K. [1 ]
机构：
[1] All India Inst Med Sci, Clin Pharmacol, New Delhi, India
[2] All India Inst Med Sci, Med Oncol, New Delhi, India
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
335O
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Development and validation of a nomogram to predict poor efficacy of imatinib in the treatment of newly diagnosed chronic phase chronic myeloid leukemia patients
    Li, Yuxin
    Zhang, Yilin
    Wang, Jin
    He, Aili
    Zhang, Wanggang
    Cao, Xingmei
    Chen, Yinxia
    Liu, Jie
    Zhang, Pengyu
    Wang, Jianli
    Zhao, Wanhong
    Yang, Yun
    Meng, Xin
    Chen, Sheping
    Zhang, Longjin
    Wang, Ting
    Wang, Xugeng
    Ma, Xiaorong
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [22] Imatinib mesylate in newly diagnosed patients of chronic myeloid leukemia chronic phase: A comparative study
    Jacob, L. A.
    Bapsy, P. P.
    Govindbabu, K.
    Lokanatha, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania
    Nasser, Ahlam
    Hussein, Ally
    Chamba, Clara
    Yonazi, Mbonea
    Mushi, Rosemary
    Schuh, Anna
    Luzzatto, Lucio
    BLOOD ADVANCES, 2021, 5 (05) : 1403 - 1411
  • [24] Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib
    McLean, LA
    Gathmann, I
    Capdeville, R
    Polymeropoulos, MH
    Dressman, M
    CLINICAL CANCER RESEARCH, 2004, 10 (01) : 155 - 165
  • [25] PHARMACOGENETICS OF IMATINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS SHOWS EVIDENCE OF ASSOCIATION BETWEEN IMATINIB TRANSPORTERS AND METABOLIZING ENZYMES GENOTYPE AND MOLECULAR RESPONSE
    Soverini, S.
    Angelini, S.
    Barnett, M.
    Turrini, E.
    Thornquist, M.
    Ravegnini, G.
    Rosti, G.
    Gnani, A.
    Colarossi, S.
    Hrelia, P.
    Kalebic, T.
    Baccarani, M.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 60 - 60
  • [26] Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate
    Espinet, Blanca
    Carla Oliveira, Ana
    Boque, Concepcion
    Domingo, Alicia
    Alonso, Esther
    Sole, Francesc
    HAEMATOLOGICA, 2005, 90 (04) : 556 - 558
  • [27] RNA Expression and Polymorphisms in Imatinib Influx and Efflux Transporters Influence Molecular Response to Imatinib Therapy in Newly Diagnosed Patients with Chronic Myeloid Leukemia.
    Balasubramanian, Poonkuzhali
    Markose, Preetha
    Anandhan, Senthamizh Selvi
    Sahu, Ramkrishna
    Kumaraswamy, Vinodhini
    Srivastava, Vivi
    Ahmed, Rayaz
    Abraham, Aby
    George, Biju
    Chandy, Mammen
    Srivastava, Alok
    Mathews, Vikram
    BLOOD, 2012, 120 (21)
  • [28] High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Goldberg, Stuart L.
    Powell, Bayard L.
    Giles, Francis J.
    Wetzler, Meir
    Akard, Luke
    Burke, John M.
    Kerr, Robert
    Saleh, Mansoor
    Salvado, August
    McDougall, Karen
    Albitar, Maher
    Radich, Jerald
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4754 - 4759
  • [29] Multicenter experience with imatinib, mesylate in newly diagnosed chronic myeloid leukemia (CML) patients
    Carella, A. M.
    Lerma, E.
    Orlandi, E.
    Lazzarino, M.
    Annunziata, M.
    Ferrara, F.
    Pungolino, E.
    Morra, E.
    Miglino, M.
    Gobbi, M.
    BLOOD, 2007, 110 (11) : 210B - 210B
  • [30] Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
    John Goldman
    Nature Clinical Practice Oncology, 2005, 2 : 126 - 127
12345